Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009

Vaccine

Volumn 30, Issue 3, 2012, Pages 565-571

  von Gottberg, Anne ^a,b,c   Cohen, Cheryl ^a,d   Whitelaw, Andrew ^e   Chhagan, Meera ^f   Flannery, Brendan ^g   Cohen, Adam L ^g   de Gouveia, Linda ^a,b,c   Plessis, Mignon du ^a,b,c   Madhi, Shabir A ^a,c,h   Klugman, Keith P ^a,b,c,i  

^a NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF KWAZULU NATAL   (South Africa)

^g NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial meningitis; Haemophilus influenzae serotype b; Hib; Laboratory based surveillance; Vaccine

Indexed keywords

COMBACTHIB; DIPHTHERIA VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PERTUSSIS VACCINE; POLYRIBOSYLRIBITOL PHOSPHATE COVALENTLY BOUND TO TETANUS TOXOID PLUS DIPHTHERIA PLUS PERTUSSIS (WHOLE CELL) VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ARTICLE; CELLULITIS; CHILD; CHILDHOOD DISEASE; DIPHTHERIA; DISEASE SURVEILLANCE; DRUG TREATMENT FAILURE; EPIGLOTTITIS; FEMALE; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE A; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS INFLUENZAE TYPE F; HAEMOPHILUS MENINGITIS; HEALTH STATUS; HEMOPHILUS INFLUENZA TYPE B INFECTION; HUMAN; IMMUNIZATION; INFECTION COMPLICATION; INFLUENZA VACCINATION; INVASIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OSTEOMYELITIS; PERTUSSIS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SEPSIS; SOUTH AFRICA; TETANUS;

CHILD, PRESCHOOL; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; SOUTH AFRICA; VACCINATION;

EID: 84355165240     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.066     Document Type: Article

References (49)

1. Murphy T.V., White K.E., Pastor P., Gabriel L., Medley F., Granoff D.M., et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 1993, 269(January (2)):246-248.
2. Adegbola R.A., Usen S.O., Weber M., Lloyd-Evans N., Jobe K., Mulholland K., et al. Haemophilus influenzae type b meningitis in the Gambia after introduction of a conjugate vaccine. Lancet 1999, 354(September (9184)):1091-1092.
3. Cowgill K.D., Ndiritu M., Nyiro J., Slack M.P., Chiphatsi S., Ismail A., et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 2006, 296(August (6)):671-678.
4. Lee E.H., Lewis R.F., Makumbi I., Kekitiinwa A., Ediamu T.D., Bazibu M., et al. Haemophilus influenzae type b conjugate vaccine is highly effective in the Ugandan routine immunization program: a case-control study. Trop Med Int Health 2008, 13(April (4)):495-502.
5. Adegbola R.A., Secka O., Lahai G., Lloyd-Evans N., Njie A., Usen S., et al. Elimination of Haemophilus influenzae type b (Hib) disease from the Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366(July (9480)):144-150.
6. Cisse M.F., Breugelmans J.G., Ba M., Diop M.B., Faye P.C., Mhlanga B., et al. The Elimination of Haemophilus influenzae type b meningitis following conjugate vaccine introduction in Senegal. Pediatr Infect Dis J 2010, 29(June (6)):499-503.
7. Ojo L.R., O'Loughlin R.E., Cohen A.L., Loo J.D., Edmond K.M., Shetty S.S., et al. Global use of Haemophilus influenzae type b conjugate vaccine. Vaccine 2010, 28(October (43)):7117-7122.
8. WHO position paper on Haemophilus influenzae type b conjugate vaccines (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record). Wkly Epidemiol Rec 2006, 81(November (47)):445-452.
9. Madhi S.A., Petersen K., Khoosal M., Huebner R.E., Mbelle N., Mothupi R., et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002, 21(April (4)):315-321.
10. Hussey G., Hitchcock J., Schaaf H., Coetzee G., Hanslo D., van Schalkwyk E., et al. Epidemiology of invasive Haemophilus influenzae infections in Cape Town. South Africa. Ann Trop Paediatr 1994, 14(2):97-103.
11. Madhi S.A., Kuwanda L., Saarinen L., Cutland C., Mothupi R., Kayhty H., et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine 2005, 23(December (48-49)):5517-5525.
12. Mangtani P., Mulholland K., Madhi S.A., Edmond K., O'Loughlin R., Hajjeh R. Haemophilus influenzae type b disease in HIV-infected children: a review of the disease epidemiology and effectiveness of Hib conjugate vaccines. Vaccine 2010, 28(February (7)):1677-1683.
13. Dorrington R.E., Bradshaw D., Budlender D. HIV/AIDS profile of the provinces of South Africa - indicators for 2003 2003, Centre for Actuarial Research, Medical Research Council and the Actuarial Society of South Africa.
14. Huebner R.E., Klugman K.P., Matai U., Eggers R., Hussey G. Laboratory surveillance for Haemophilus influenzae type b, meningococcal, and pneumococcal disease. Haemophilus Surveillance Working Group. S Afr Med J 1999, 89(September (9)):924-925.
15. von Gottberg A., de Gouveia L., Madhi S.A., du Plessis M., Quan V., Soma K., et al. Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. Bull World Health Organ 2006, 84(October (10)):811-818.
16. World Health Organization. Immunization, vaccines and biologicals, IVB document centre: WHO vaccine-preventable diseases: monitoring system - 2010 global summary. Available at: [accessed 30.03.10]. http://www.who.int/immunization_monitoring/data/zaf.pdf.
17. Radstrom P., Backman A., Qian N., Kragsbjerg P., Pahlson C., Olcen P. Detection of bacterial DNA in cerebrospinal fluid by an assay for simultaneous detection of Neisseria meningitidis. Haemophilus influenzae, and streptococci using a seminested PCR strategy. J Clin Microbiol 1994, 32(November (11)):2738-2744.
18. Maaroufi Y., De Bruyne J.M., Heymans C., Crokaert F. Real-time PCR for determining capsular serotypes of Haemophilus influenzae. J Clin Microbiol 2007, 45(July (7)):2305-2308.
19. Singh E., Cohen C., Govender N., Meiring S. A description of HIV testing strategies at 21 laboratories in South Africa. Commun Dis Surv Bull 2008, 6(November (4)):16-17. for GERMS-SA.
20. Falla T.J., Crook D.W., Brophy L.N., Maskell D., Kroll J.S., Moxon E.R. PCR for capsular typing of Haemophilus influenzae. J Clin Microbiol 1994 Oct, 32(10):2382-2386.
21. Sandstedt S.A., Zhang L., Patel M., McCrea K.W., Qin Z., Marrs C.F., et al. Comparison of laboratory-based and phylogenetic methods to distinguish between Haemophilus influenzae and H. haemolyticus. J Microbiol Methods 2008, 75(October (2)):369-371.
22. Brophy L.N., Kroll J.S., Ferguson D.J., Moxon E.R. Capsulation gene loss and 'rescue' mutations during the Cap+ to Cap- transition in Haemophilus influenzae type b. J Gen Microbiol 1991, 137(November (11)):2571-2576.
23. Statistics South Africa. StatsOnline: populations statistics. Available at: [accessed 27.07.09]. http://www.statssa.gov.za/timeseriesdata/timeseriesdata.asp.
24. Dean A.D., Dean J.A., Burton J.H. Epi Info, version 6.04: a word processing, database, and statistics program for epidemiology on microcomputers 1996, Centers for Disease Control and Prevention, Atlanta.
25. Barbour M.L., Mayon-White R.T., Coles C., Crook D.W., Moxon E.R. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis 1995, 171(January (1)):93-98.
26. Ghaffar F., Barton T., Lozano J., Muniz L.S., Hicks P., Gan V., et al. Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life. Clin Infect Dis 2004 Oct 1, 39(7):930-938.
27. Yeh S.H., Zangwill K.M., Lee H., Chang S.J., Wong V.I., Greenberg D.P., et al. Heptavalent pneumococcal vaccine conjugated to outer membrane protein of Neisseria meningitidis serogroup b and nasopharyngeal carriage of Streptococcus pneumoniae in infants. Vaccine 2003, 21(June (19-20)):2627-2631.
28. Prymula R., Kriz P., Kaliskova E., Pascal T., Poolman J., Schuerman L. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine 2009, 28(December (1)):71-78.
29. Ladhani S., Slack M.P., Heys M., White J., Ramsay M.E. Fall in Haemophilus influenzae serotype b (Hib) disease following implementation of a booster campaign. Arch Dis Child 2008, 93(August (8)):665-669.
30. McVernon J., Trotter C.L., Slack M.P., Ramsay M.E. Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004, 329(September (7467)):655-658.
31. Ramsay M.E., McVernon J., Andrews N.J., Heath P.T., Slack M.P. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003, 188(August (4)):481-485.
32. Vidor E., Hoffenbach A., Fletcher M.A. Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses. Curr Med Res Opin 2001, 17(3):197-209.
33. Eskola J., Ward J., Dagan R., Goldblatt D., Zepp F., Siegrist C.A. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 1999, 354(December (9195)):2063-2068.
34. Rijkers G.T., Vermeer-de Bondt P.E., Spanjaard L., Breukels M.A., Sanders E.A. Return of Haemophilus influenzae type b infections. Lancet 2003, 361(May (9368)):1563-1564.
35. Howie S.R., Antonio M., Akisanya A., Sambou S., Hakeem I., Secka O., et al. Re-emergence of Haemophilus influenzae type b (Hib) disease in the Gambia following successful elimination with conjugate Hib vaccine. Vaccine 2007, 25(August (34)):6305-6309.
36. Madhi S.A., Adrian P., Kuwanda L., Jassat W., Jones S., Little T., et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine 2007, 25(March (13)):2451-2457.
37. Daza P., Banda R., Misoya K., Katsulukuta A., Gessner B.D., Katsande R., et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 2006, 24(September (37-39)):6232-6239.
38. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985, 63(6):1055-1068.
39. Nunes M.C., von Gottberg A., de Gouveia L., Cohen C., Moore D.P., Klugman K.P., et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011, 25(February (4)):453-462.
40. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 1999, 5(May (3)):336-345.
41. Ribeiro G.S., Reis J.N., Cordeiro S.M., Lima J.B., Gouveia E.L., Petersen M., et al. Prevention of Haemophilus influenzae type b (Hib) meningitis and emergence of serotype replacement with type a strains after introduction of Hib immunization in Brazil. J Infect Dis 2003, 187(January (1)):109-116.
42. Cerquetti M., gli Atti M.L., Cardines R., Salmaso S., Renna G., Mastrantonio P. Invasive type e Haemophilus influenzae disease in Italy. Emerg Infect Dis 2003, 9(February (2)):258-261.
43. Bajanca P., Canica M. Emergence of nonencapsulated and encapsulated non-b-type invasive Haemophilus influenzae isolates in Portugal (1989-2001). J Clin Microbiol 2004, 42(February (2)):807-810.
44. Ribeiro G.S., Lima J.B., Reis J.N., Gouveia E.L., Cordeiro S.M., Lobo T.S., et al. Haemophilus influenzae meningitis 5 years after introduction of the Haemophilus influenzae type b conjugate vaccine in Brazil. Vaccine 2007, 25(May (22)):4420-4428.
45. Ladhani S., Ramsay M.E., Chandra M., Slack M.P. No evidence for Haemophilus influenzae serotype replacement in Europe after introduction of the Hib conjugate vaccine. Lancet Infect Dis 2008, 8(May (5)):275-276.
46. Ladhani S., Slack M.P., Heath P.T., von Gottberg A., Chandra M., Ramsay M.E. Invasive Haemophilus influenzae Disease Europe, 1996-2006. Emerg Infect Dis 2010, 16(March (3)):455-463.
47. Adam H.J., Richardson S.E., Jamieson F.B., Rawte P., Low D.E., Fisman D.N. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine 2010, 28(May (24)):4073-4078.
48. Dworkin M.S., Park L., Borchardt S.M. The changing epidemiology of invasive Haemophilus influenzae disease, especially in persons>or=65 years old. Clin Infect Dis 2007, 44(March (6)):810-816.
49. Schuchat A., Messonnier N.R. From pandemic suspect to the postvaccine era: the Haemophilus influenzae story. Clin Infect Dis 2007, 44(March (6)):817-819.